Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.

Electronic supplementary material

The online version of this article (doi:10.1186/s40409-017-0109-8) contains supplementary material, which is available to authorized users.

Related collections

Most cited references 72

Record: found
Abstract: found
Article: not found

Application of acute phase protein measurements in veterinary clinical chemistry.

Henrik Hagbard Petersen, Jens Peter Nielsen, Peter Mikael Helweg Heegaard (2004)

The body's early defence in response to trauma, inflammation or infection, the acute phase response, is a complex set of systemic reactions seen shortly after exposure to a triggering event. One of the many components is an acute phase protein response in which increased hepatic synthesis leads to increased serum concentration of positive acute phase proteins. The serum concentration of these acute phase proteins returns to base levels when the triggering factor is no longer present. This paper provides a review of the acute phase proteins haptoglobin, C-reactive protein and serum amyloid A and their possible use as non-specific indicators of health in large animal veterinary medicine such as in the health status surveillance of pigs at the herd level, for the detection of mastitis in dairy cattle and for the prognosis of respiratory diseases in horses.

0 comments Cited 190 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Evolutionary families of peptidase inhibitors.

Neil D Rawlings, Neil D. Rawlings, J. Barrett (2004)

The proteins that inhibit peptidases are of great importance in medicine and biotechnology, but there has never been a comprehensive system of classification for them. Some of the terminology currently in use is potentially confusing. In the hope of facilitating the exchange, storage and retrieval of information about this important group of proteins, we now describe a system wherein the inhibitor units of the peptidase inhibitors are assigned to 48 families on the basis of similarities detectable at the level of amino acid sequence. Then, on the basis of three-dimensional structures, 31 of the families are assigned to 26 clans. A simple system of nomenclature is introduced for reference to each clan, family and inhibitor. We briefly discuss the specificities and mechanisms of the interactions of the inhibitors in the various families with their target enzymes. The system of families and clans of inhibitors described has been implemented in the MEROPS peptidase database (http://merops.sanger.ac.uk/), and this will provide a mechanism for updating it as new information becomes available.

0 comments Cited 137 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.

D F O'Shaughnessy, C Atterbury, P Bolton Maggs … (2004)

The indications for transfusing fresh-frozen plasma (FFP), cryoprecipitate and cryosupernatant plasma are very limited. When transfused they can have unpredictable adverse effects. The risks of transmitting infection are similar to those of other blood components unless a pathogen-reduced plasma (PRP) is used. Of particular concern are allergic reactions and anaphylaxis, transfusion-related acute lung injury, and haemolysis from transfused antibodies to blood group antigens, especially A and B. FFP is not indicated in disseminated intravascular coagulation without bleeding, is only recommended as a plasma exchange medium for thrombotic thrombocytopenic purpura (for which cryosupernatant is a possible alternative), should never be used to reverse warfarin anticoagulation in the absence of severe bleeding, and has only a very limited place in prophylaxis prior to liver biopsy. When used for surgical or traumatic bleeding, FFP and cryoprecipitate doses should be guided by coagulation studies, which may include near-patient testing. FFP is not indicated to reverse vitamin K deficiency for neonates or patients in intensive care units. PRP may be used as an alternative to FFP. In the UK, PRP from countries with a low bovine spongiform encephalopathy incidence is recommended by the Departments of Health for children born after 1 January 1996. Arrangements for limited supplies of single donor PRP of non-UK origin are expected to be completed in 2004. Batched pooled commercially prepared PRP from donors in the USA (Octaplas) is licensed and available in the UK. FFP must be thawed using a technique that avoids risk of bacterial contamination. Plastic packs containing any of these plasma products are brittle in the frozen state and must be handled with care.

0 comments Cited 120 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Rui Seabra Ferreira Jr: +55 14 3880 7108 , rseabra@cevap.unesp.br

Luciana Curtolo de Barros: luciana@cevap.unesp.br

Luciana Patrícia Fernandes Abbade: lfabbade@fmb.unesp.br

Silvia Regina Catharino Sartori Barraviera: srbarraviera@cevap.org.br

Maria Regina Cavariani Silvares: mregina@fmb.unesp.br

Leticia Gomes de Pontes: lekapontes@hotmail.com

Lucilene Delazari dos Santos: lucilene@cevap.unesp.br

Benedito Barraviera: bbviera@cevap.unesp.br

Journal

Journal ID (nlm-ta): J Venom Anim Toxins Incl Trop Dis

Journal ID (iso-abbrev): J Venom Anim Toxins Incl Trop Dis

Title: The Journal of Venomous Animals and Toxins Including Tropical Diseases

Publisher: BioMed Central (London )

ISSN (Electronic): 1678-9199

Publication date (Electronic): 4 April 2017

Publication date PMC-release: 4 April 2017

Publication date Collection: 2017

Volume: 23

Electronic Location Identifier: 21

Affiliations

[1 ]GRID grid.410543.7, Graduate Program in Tropical Diseases, Botucatu Medical School, , São Paulo State University (UNESP – Univ Estadual Paulista), ; Botucatu, SP Brazil

[2 ]GRID grid.410543.7, Center for the Study of Venoms and Venomous Animals (CEVAP), , São Paulo State University (UNESP – Univ Estadual Paulista), ; Botucatu, SP Brazil

[3 ]GRID grid.410543.7, Department of Dermatology and Radiology, Botucatu Medical School, , São Paulo State University (UNESP – Univ Estadual Paulista), ; Botucatu, SP Brazil

[4 ]CEVAP/UNESP, Avenida José Barbosa de Barros, 1780, Botucatu, SP CEP 18610-307 Brazil

Article

Publisher ID: 109

DOI: 10.1186/s40409-017-0109-8

PMC ID: 5379742

PubMed ID: 28396682

SO-VID: 72584753-e8de-48c5-8b3b-3cb0ec75606f

License:

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

History

Date received : 14 January 2017

Date accepted : 16 March 2017

Funding

Funded by: National Counsel of Technological and Scientific Development - Brazil

Award ID: 310395/2014-3

Award ID: 563582/2010-3

Award Recipient : Benedito Barraviera

Funded by: FundRef http://dx.doi.org/10.13039/501100002322, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior;

Award ID: 23038.006285/2011-21

Award Recipient : Benedito Barraviera

Custom metadata

Keywords: fibrin sealant,snake venom,cryoprecipitate coagulum,thrombin-like enzyme,buffaloes

Data availability:

Keywords: fibrin sealant, snake venom, cryoprecipitate coagulum, thrombin-like enzyme, buffaloes

Heterologous fibrin sealant derived from snake venom: from bench to bedside – an overview

Read this article at

Abstract

Electronic supplementary material

Related collections

SciELO Brazil

Most cited references 72

Application of acute phase protein measurements in veterinary clinical chemistry.

Evolutionary families of peptidase inhibitors.

Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 273

Cited by 39

Most referenced authors 651